Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Nov 4, 2024Closes
Oct 20, 2027Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Health
Eligible applicants: City or township governments, Others (see text field entitled "Additional Information on Eligibility" for clarification), State governments, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Independent school districts, Public housing authorities/Indian housing authorities, For profit organizations other than small businesses, Special district governments, Public and State controlled institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Small businesses, Native American tribal organizations (other than Federally recognized tribal governments), Private institutions of higher education, County governments, Native American tribal governments (Federally recognized)
Description
Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.